<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676234</url>
  </required_header>
  <id_info>
    <org_study_id>2008-11021991</org_study_id>
    <nct_id>NCT00676234</nct_id>
  </id_info>
  <brief_title>Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure</brief_title>
  <official_title>Recombinant Human Erythropoietin Use in ICU Patients: Does it Prevent Acute Renal Failure?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study aiming to assess the effect of two doses of rhu EPO on urine NGAL concentration&#xD;
      and on serum cystatin C and creatinine levels in critically ill patients at risk of ARF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research plan Open-label randomized trial Twelve months duration trial Setting: Medical and&#xD;
      Surgical Intensive Care Unit of the University Hospitals of Geneva Start of trial: Mid-May&#xD;
      2008&#xD;
&#xD;
      Patients randomly allocated to 2 treatment groups (20 patients per group), or a control group&#xD;
      (40 patients):&#xD;
&#xD;
        -  Group 1: control group (40 patients)&#xD;
&#xD;
        -  Group 2 : 20000 IU rhu Epo (20 patients) administered by the i.v. route&#xD;
&#xD;
        -  Group 3 : 40000 IU rhu Epo (20 patients) administered by the i.v. route&#xD;
&#xD;
      3.2. Trial design Day 0 Consent form signed Patients randomly allocated to control or&#xD;
      treatment groups (20000 and 40000 IU) Serum Cystatin C determination Serum Creatinine&#xD;
      determination Urinary NGAL determination Administration of intravenous rhu Epo on Day 0 or no&#xD;
      Epo (control group) Day 2 At 48 hr after rhu EPO injection, samples will be taken for&#xD;
&#xD;
        -  Serum Cystatin C determination&#xD;
&#xD;
        -  Serum Creatinine determination&#xD;
&#xD;
        -  Urinary NGAL determination Day 4 At 96 hr after rhu EPO injection, samples will be taken&#xD;
           for&#xD;
&#xD;
        -  Serum Cystatin C determination&#xD;
&#xD;
        -  Serum Creatinine determination&#xD;
&#xD;
        -  Urinary NGAL determination&#xD;
&#xD;
      Stopping rules&#xD;
&#xD;
      The trial for an individual subject, parts of the trial or the entire trial will be stopped&#xD;
      when:&#xD;
&#xD;
        -  at Day 4 for an individual subject&#xD;
&#xD;
        -  after enrollment of 80 patients&#xD;
&#xD;
      Treatment The treatment will consist of intravenous (i.v.) injections of recombinant human&#xD;
      erythropoietin (r-hu-EPO). The trial medication will be provided by JANSSEN-CILAG AG. The&#xD;
      brand name is EPREXÂ® which is epoietinum-alpha in sterile buffered solution for i.v. or s.c.&#xD;
      injection.&#xD;
&#xD;
      Patient group 1 will not receive EPO treatment. Patient group 2 will receive 20'000 U of rhu&#xD;
      EPO and patient group 3 will receive 40'000 U of rhu EPO (i.v. route).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change (%) from baseline in urinary NGAL concentration at 96 hr after rhu EPO injection</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean change (%) from baseline in serum Cystatin C concentration at 96 hr after rhu EPO injection</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Renal Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of intravenous rhu Epo on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetinum</intervention_name>
    <description>Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Eprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients at risks for acute tubular necrosis (patients with mechanical ventilation,&#xD;
             patients with sepsis, in the post-operative state, with hemodynamic impairment or with&#xD;
             previous chronic renal failure.&#xD;
&#xD;
          -  Consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with malignant hypertension&#xD;
&#xD;
          -  Patients with systolic BP &gt; 150 mmHg at enrollment&#xD;
&#xD;
          -  Patients with Hb level &gt; 120g/L&#xD;
&#xD;
          -  Patients with acute coronaropathy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with urine output &lt; 600 ml/12 h&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Saudan, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Unit Geneva University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Unit, Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <last_update_submitted>June 26, 2009</last_update_submitted>
  <last_update_submitted_qc>June 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr P. Saudan</name_title>
    <organization>Nephrology Unit</organization>
  </responsible_party>
  <keyword>erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

